logo

For the Inventor, By the Inventor

Milan, Italy

Italfarmaco Spa


USPTO Granted Patents = 49

% Expired Patents = 2.0



Trademarks = 6

Forward Citations = 251

Loading Chart...
Loading Chart...

90 inventors (with patents filed for the assignee):

goldMedal Paolo Mascagni (21 out of 21 patents)

silverMedal Flavio Leoni (10 out of 10 patents)

bronzeMedal Giancarlo Sportoletti (10 out of 12 patents)

4.  Massimo Pinori (8 out of 13 patents)

5.  Gianni Gromo (7 out of 7 patents)

6.  Pietro Cremonesi (7 out of 7 patents)

7.  Francesca Benedini (5 out of 34 patents)

8.  Alberto Sala (5 out of 10 patents)

9.  Gianluca Fossati (4 out of 4 patents)

10.  Giorgio Bertolini (4 out of 19 patents)

11.  Roberta Cereda (4 out of 4 patents)

12.  Barbara Vergani (3 out of 3 patents)

13.  Maria Lattanzio (3 out of 3 patents)

14.  Gianfranco Pavich (3 out of 3 patents)

15.  Daniela Modena (3 out of 3 patents)


Core Competencies:
HDAC6 Inhibitors
Anti-Inflammatory Compounds
Oral Suspensions
N-Hydroxybenzamide Derivatives
Heparin Derivatives
Cytoprotective Guanidine
Pharmaceutical Compositions
Peptides
Glycosaminoglycan Salts
Enzymatic Reactions
Amino Acid Derivatives
Cardiovascular Activity

49 patents:

1. 12606519 - Process for preparing {6-[(diethylamino) methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl] carbamate having high purity (2026-04-21),
2. 12129224 - Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity (2024-10-29),
3. 11351178 - Selective HDAC6 inhibitors (2022-06-07),
4. 10745696 - HC-CDR3-only libraries with reduced combinatorial redundancy and optimized loop length distribution (2020-08-18),
5. 10688047 - Physically and chemically stable oral suspensions of givinostat (2020-06-23),
6. 10590101 - Benzo-N-hydroxy amide compounds having antitumor activity (2020-03-17),
7. 9867799 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2018-01-16),
8. 9522127 - Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes (2016-12-20),
9. 9421184 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2016-08-23),
10. 8937152 - Non-selective somatostatin analogues (2015-01-20),
11. 8765150 - Riluzole aqueous suspensions (2014-07-01),
12. 8637702 - Derivatives of N-hydroxybenzamide for treating HIV infections (2014-01-28),
13. 8273730 - Use of estriol in low doses (2012-09-25),
14. 8227515 - Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments (2012-07-24),
15. 8217079 - Method for treating Philadelphia-negative myeloproliferative syndromes (2012-07-10),
Company Overview
Italfarmaco Spa, headquartered in Milan, Italy, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative therapeutic solutions. The company specializes in selective HDAC6 inhibitors and other histone deacetylase inhibitors, targeting antitumor and anti-inflammatory activities. Italfarmaco also explores hydroxamic acid derivatives, heparin derivatives, and cytoprotective guanidine derivatives, contributing to advancements in medical treatments and enhancing patient care through its research initiatives.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

49 Patents

#45 in Milan

#187 in Italy

#14,277 in the World

Milan, IT
Milan, Italy

Italfarmaco Spa

Forward Citations = 251

90 inventors:

goldMedal Paolo Mascagni (21 out of 21 patents)

silverMedal Flavio Leoni (10 out of 10 patents)

bronzeMedal Giancarlo Sportoletti (10 out of 12 patents)

4.  Massimo Pinori (8 out of 13 patents)

5.  Gianni Gromo (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Italfarmaco Spa. Retrieved from https://idiyas.com/company/italfarmaco-spa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…